The development of deep learning and neural
networks has led to artificial intelligence (AI) gaining learning capabilities,
as a result of which some new AI tools are now better than human eyes at
recognizing patterns. This is paving the way for the emergence of a new
generation of medical diagnostic devices that are capable of surpassing the
detection skills of the best medical practitioners.
These are the latest findings of Research and Markets,
(Dublin, Ireland), a global market research company.
The ability to replicate AI has made the expertise of such
medical diagnostic devices accessible to a large number of patients.
Additionally, AI finds numerous and diverse applications in medical
diagnostics, such as image analysis for tumor detection, video detection for
gait disorders and fall prediction, biochemical tests such as for diabetes or
speech analysis of emotional state and psychiatric disorders. Hence, AI will
significantly disrupt the traditional model of medical diagnosis.
Since 2016, companies working on the development of AI for
medical imaging have made investments of more than USD 1.1 billion. In addition
to big medical diagnostic systems manufacturers, the number of Intellectual
Property (IP) newcomers is also important and growing. Unlike as in the case of
development of new medical devices, the costs for developing AI software are
moderate. As a result, the number of IP newcomers developing innovative
software is likely to continue to increase sharply over the coming years.
The emergence of several new companies, coupled with the
various advantages and new applications of AI for medical diagnostics, makes it
crucial to understand the IP position and strategy of the different players. An
analysis of the time evolution of patent publications reveals that the
development of medical diagnostic systems with built-in computer-assisted
detection features is not new, and the first patents related to this topic were
published in the 1980s. During the 1990s, Japanese manufacturers of medical
imaging systems began investing in investigations into this field to be soon
followed by European companies and later by American companies. The number of
patent families published each year increased progressively until 2015 and has
increased rapidly since then, with more than 1,100 new patent families
published in 2018. This indicates that AI in medical diagnostics is a very hot
topic that is mobilizing great R&D efforts from different players.
Among the players who have filed patents related to AI in
medical diagnostics, over 90 are newcomers, out of which most are startup firms
currently developing their first products. These products include software
solutions such as software for ultrasound imaging analysis, image resolution
improvement or real-time brain monitoring, or medical devices that are capable
of live analysis of biological parameters, such as blood glucose monitoring
apparatus, sleep monitoring sensors and ECG. Several IP newcomers are based in
the US while some are based in Israel, in Europe or in Asia. Some of these
innovative companies could become one of the next healthcare unicorns, making
them potential acquisition targets for big corporations.
